•
Jun 30, 2023

Prelude Therapeutics Q2 2023 Earnings Report

EPS
-$0.54
Previous year: -$0.58
-6.9%
Cash and Equivalents
$26.4M
Previous year: $50.7M
-47.8%
Free Cash Flow
-$28.7M
Previous year: -$19.2M
+49.0%
Total Assets
$281M
Previous year: $259M
+8.3%

Prelude Therapeutics

Prelude Therapeutics